Is MERS Another SARS? The Facts Behind Middle East Respiratory Syndrome

Article

Experts show that while Middle East Respiratory Syndrome (MERS-CoV), a viral respiratory illness, is infecting less people, it has a higher mortality rate and affects a specific target population when compared to Severe Acute Respiratory Syndrome (SARS-CoV). This research is being presented at the International Conference on Emerging and Infectious Diseases in Atlanta.

"The research conducted in this study focuses on understanding what population of individuals are most likely to become infected by MERS-CoV, compared to the population infected by SARS-CoV," says Charis Royal from Arizona State University. Understanding the population dynamics of the infected cases in both diseases can lead to understanding how the new disease will spread and if it can be compared to the SARS-CoV.

"An unusually high number of MERS-CoV cases are males with a median age of 50 years old, who have multiple chronic conditions," says Royal. " SARS-CoV, on the other hand, infects males and females nearly equally and both healthy and unhealthy individuals can be infected" she added. Both diseases spread rapidly in hospitals and hospital workers account for around 21 percent of infections in both SARS-CoV and MERS-CoV.

In 2003, multi-country outbreak of Severe Acute Respiratory Syndrome (SARS-CoV) left more than 8,000 people infected and had a death toll of more than 700. In 2012, the novel coronavirus, MERS-CoV, which is related to SARS-CoV3, was first reported in Saudi Arabia. Over the last three years, MERS-CoV has spread to 14 different countries and infected more than 1,300 individuals.

Data from the research was gathered through the World Health Organization summary reports for MERS-CoV and the cumulative data reports for the 2003 SARS-CoV outbreak.

Source: American Society for Microbiology

Newsletter

Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.

Recent Videos
 Brenna Doran PhD, MA, hospital epidemiology and infection prevention for the University of California, San Francisco, and a coach and consultant of infection prevention; Jessica Swain, MBA, MLT, director of infection prevention and control for Dartmouth Health in Lebanon, New Hampshire; and Shanina Knighton, associate professor at Case Western Reserve University School of Nursing and senior nurse scientist at MetroHealth System in Cleveland, Ohio
In a recent discussion with Infection Control Today® (ICT®), study authors Brenna Doran PhD, MA, hospital epidemiology and infection prevention for the University of California, San Francisco, and a coach and consultant of infection prevention; Jessica Swain, MBA, MLT, director of infection prevention and control for Dartmouth Health in Lebanon, New Hampshire; and Shanina Knighton, associate professor at Case Western Reserve University School of Nursing and senior nurse scientist at MetroHealth System in Cleveland, Ohio, shared their insights on how the project evolved and what the findings mean for the future.
 Futuristic UV Sanitizer with Sleek Design on a white background.  (Adobe Stock 1375983522 by Napa)